Tumor Genomic Profiling denied as non-formulary by Cigna?

Cigna's specific coverage criteria for tumor genomic profiling are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denies Tumor Genomic Profiling as Non-Formulary — and How to Appeal

Tumor genomic profiling — including comprehensive genomic sequencing and broad multi-gene molecular panels — is a diagnostic service that some health plans, including those administered by Cigna, manage through a laboratory benefit structure that functions similarly to a drug formulary. Tests and specific panel types are assigned preferred or non-preferred status, and tests ordered from non-contracted laboratories or using codes outside the preferred list may be denied as "non-formulary."

### Why This Denial Happens

A non-formulary denial on a genomic test typically means one of three things: the specific test code or panel requested is not on Cigna's approved list of covered genomic tests; the laboratory performing the test is not in Cigna's network or approved laboratory panel; or the test was ordered without prior authorization from a laboratory benefit management program that Cigna has contracted to manage genomic testing. The denial is usually a coverage-tier or administrative issue rather than a clinical judgment about the test's value.

### Why It Is Appealable

Non-formulary denials are among the most administratively correctable. The first step is confirming whether the denial is about the test itself, the performing laboratory, or a missing authorization. Once the specific barrier is identified, the appeal can target it precisely — either by demonstrating that the test meets criteria for an exception, or that an equivalent in-network test cannot provide the clinically necessary information. When no in-network equivalent exists for the patient's clinical situation, exception coverage is generally available as a matter of law and plan terms.

### Federal Appeal Framework

• Internal appeal: Submit within the timeframe on the denial notice (typically 180 days for ACA-compliant plans). Cigna must respond within 30 days for pre-service and 60 days for post-service appeals.
• External review (ACA §2719): After exhausting the internal process, you have approximately four months to request independent external review by an IRO. The IRO decision is binding on Cigna.
• ERISA §503: Employer-plan enrollees are entitled to full-and-fair review and may request the complete administrative record.
• Expedited review: If clinical delay would seriously jeopardize health, expedited review is available with decisions typically required within 72 hours.

### Documentation to Gather

1. Test order and performing laboratory documentation — the exact test code, panel name, and CLIA-certified laboratory performing the test. 2. In-network equivalence analysis — confirmation from the ordering oncologist (or the laboratory) that no in-network laboratory offers a clinically equivalent panel for this indication. 3. Ordering oncologist's medical-necessity letter — a signed letter explaining why the specific test from the specific laboratory is necessary and why substitution with a different panel or laboratory would compromise clinical utility. 4. Diagnosis and treatment context — current pathology report and clinical notes establishing the cancer type, stage, and the clinical question the test is intended to answer. 5. Applicable guideline reference — reference to the relevant NCCN guideline or equivalent professional society recommendation supporting this specific testing approach.

### Criteria-Mapping Structure

Review Cigna's medical coverage policy and laboratory benefit management criteria for the specific test code at cigna.com. Identify the exact reason for non-formulary status — test code, laboratory, or authorization gap — and address it directly. Build a response that either demonstrates the test qualifies for an exception under the plan's non-formulary exception process, or shows that the specific panel and laboratory are the only clinically appropriate option for this patient. Submit this as a structured letter with each point clearly labeled.